文献速递类风湿关节炎

托珠单抗与心血管疾病风险:类风湿关节炎患者中生物改善病情抗风湿药的直接比较

Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2019-01-01

该队列研究利用2006-2015年Medicare与MarketScan理赔数据,纳入88,463例2010年1月1日后起始生物制剂治疗的类风湿关节炎患者,比较托珠单抗与其他生物制剂的心血管复合终点风险。结果显示托珠单抗的心血管风险与依那西普及多种其他生物制剂相当。

要点

  • Medicare数据中,与托珠单抗相比,英夫利西单抗调整后HR为1.61(95%CI 1.22-2.12)。
  • MarketScan数据中,托珠单抗与任何其他生物制剂的心血管风险均无统计学显著差异。
  • 在链接MBDA检测结果的亚组(n=4,156)中外部调整疾病活动度后结果稳健。

核心结论

  • 托珠单抗的心血管疾病风险与依那西普及多种其他用于治疗类风湿关节炎的生物制剂相当。

研究设计与样本

  • 采用2006-2015年Medicare与MarketScan理赔数据开展的队列研究。
  • 纳入2010年1月1日后起始生物改善病情抗风湿药治疗的类风湿关节炎患者,共88,463例。
  • 主要结局为心肌梗死、卒中和致死性心血管疾病的复合终点,采用经验证的方法评估。
  • 利用多生物标志物疾病活动度(MBDA)评分在亚组分析(约占生物制剂起始治疗的5-10%)中评估RA疾病活动度所致潜在混杂的影响。

主要发现

  • Medicare患者中复合心血管事件的粗发生率(每1,000患者年)从依那西普使用者的11.8(95%CI 9.7-14.4)到英夫利西单抗使用者的17.3(95%CI 15.2-19.7)。
  • 肿瘤坏死因子抑制剂汇总使用者的粗发生率为15.0(95%CI 13.9-16.3)。
  • 与托珠单抗相比,调整后HR分别为:阿巴西普1.01(95%CI 0.79-1.28),利妥昔单抗1.16(95%CI 0.89-1.53),依那西普1.10(95%CI 0.80-1.51),阿达木单抗1.33(95%CI 0.99-1.80),英夫利西单抗1.61(95%CI 1.22-2.12)。
  • 使用MarketScan数据时,托珠单抗与任何其他生物制剂之间的心血管疾病风险均无统计学显著差异。
  • 在链接MBDA检测结果的亚组(n=4,156)中,经外部调整控制RA疾病活动度后,结果稳健。

关键数值与推荐

  • 复合心血管事件粗发生率(每1,000患者年):依那西普11.8(95%CI 9.7-14.4),英夫利西单抗17.3(95%CI 15.2-19.7)。
  • 肿瘤坏死因子抑制剂汇总使用者粗发生率15.0(95%CI 13.9-16.3)。
  • 与托珠单抗相比调整后HR:阿巴西普1.01(95%CI 0.79-1.28),利妥昔单抗1.16(95%CI 0.89-1.53),依那西普1.10(95%CI 0.80-1.51),阿达木单抗1.33(95%CI 0.99-1.80),英夫利西单抗1.61(95%CI 1.22-2.12)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Multiple studies have shown seemingly unfavorable changes in lipid profiles associated with interleukin-6 receptor (IL-6R) antagonists and some other therapies for rheumatoid arthritis. The aim of this study was to assess the real-world cardiovascular disease (CVD) risk associated with tocilizumab, the first anti-IL-6R medication approved for the treatment of RA. METHODS: We conducted a cohort study using 2006-2015 Medicare and MarketScan claims for patients with RA in whom treatment with biologic disease-modifying antirheumatic drugs was initiated after January 1, 2010. The primary outcome was a composite of myocardial infarction, stroke, and fatal CVD, assessed using a validated method. The influence of potential confounding due to RA disease activity was assessed in a subgroup analysis (~5-10% of biologic therapy initiations) using the multi-biomarker disease activity (MBDA) score. RESULTS: A total of 88,463 patients with RA were included. The crude incidence rate (IR) per 1,000 patient-years for composite CVD events among Medicare patients ranged from 11.8 (95% confidence interval [95% CI] 9.7-14.4) for etanercept users to 17.3 (95% CI 15.2-19.7) for infliximab users. The crude IR for pooled users of a tumor necrosis factor inhibitor was 15.0 (95% CI 13.9-16.3). Compared to tocilizumab, the corresponding adjusted hazard ratios (HRs) were 1.01 (95% CI 0.79-1.28) for abatacept, 1.16 (95% CI 0.89-1.53) for rituximab, 1.10 (95% CI 0.80-1.51) for etanercept, 1.33 (95% CI 0.99-1.80) for adalimumab, and 1.61 (95% CI 1.22-2.12) for infliximab. There were no statistically significant differences in the risk of CVD between tocilizumab and any other biologic when MarketScan data were used. Results were robust in numerous subgroup analyses and after external adjustment to control for RA disease activity in the subgroup of patients with linked MBDA test results (n = 4,156). CONCLUSION: Tocilizumab was associated with a CVD risk comparable to that for etanercept as well as a number of other biologics used for the treatment of RA.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Xie F, Yun H, Levitan EB, et al. Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients. Arthritis Care Res (Hoboken). 2019. PMID: 30175897. doi:10.1002/acr.23737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。